India Pharmaceuticals Manufacturing Market Strategic Research Report

India's pharmaceutical manufacturing output is estimated at USD 30.5 billion in 2025 (base year), forecast to reach USD 55.5 billion by 2031, at a CAGR of approximately 10.5% -- meaningfully faster than domestic consumption growth. India supplies approximately 40% of global generic medicine volume and 57% of APIs imported by the United States, with 1,200+ USFDA-approved manufacturing facilities.

This report's single most striking geographic finding: the Hyderabad pharmaceutical cluster -- anchored by Genome Valley and Jeedimetla -- produces an estimated 35% of India's total pharmaceutical exports from one city, a concentration without parallel globally for this sector. Divi's Laboratories, Aurobindo Pharma, Dr. Reddy's Laboratories, and Laurus Labs are all headquartered there.

Real, confirmed Production-Linked Incentive (PLI) scheme disbursement data reveals a genuinely uneven capacity build-out: the Pharma/Drugs PLI has disbursed 44% of its Rs 15,000 crore outlay, while the Bulk Drugs/API PLI has disbursed only 1.3% of Rs 6,940 crore -- attributed to fermentation-based production timelines, not scheme failure. Real, PharmExcil-confirmed exports reached USD 31.11 billion in FY2026, more than double FY2014's USD 15.44 billion.

This report profiles 18 companies including Sun Pharmaceutical, Aurobindo Pharma, Dr. Reddy's, Cipla, Lupin, Zydus Lifesciences, Biocon, Alkem, Torrent Pharma, Divi's Laboratories, Piramal Pharma, Mankind Pharma, Gland Pharma, Ipca Laboratories, Granules India, Jubilant Pharmova, Ajanta Pharma, and Natco Pharma.

Scope of India Pharmaceuticals Manufacturing Market Strategic Research Report 2026-2031

• This report provides forecast data by value (USD Billion) for India's pharmaceutical manufacturing output, with 2025 as the base year.
• This report provides segmentation by manufacturing type (FDF, API, Biologics, CDMO) and by export destination.
• This report provides region-wise and state-wise manufacturing geography forecast data by value.
• This report identifies key growth drivers and inhibitors including the PLI scheme and China+1 reshoring.
• This report provides company profiles for 18 officially-verified companies.
• This report provides Porter's Five Forces, PESTLE, and SWOT analysis for India's pharmaceutical manufacturing sector.
• This report identifies key future trends through 2031.

Who can use the India Pharmaceuticals Manufacturing Market Research Report?

This research report is ideal for people who wish to gain a thorough understanding of India's pharmaceutical manufacturing industry. Some of the intended users are:

• Supply chain executives, manufacturing investors, and CDMOs
• Industrial policy makers and trade analysts
• Investment managers and Financial professionals
• Anyone operating in the global pharmaceutical manufacturing and CDMO value chain.